lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-22. Anything still debated is marked as such rather than presented as settled.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Three amino acids, histidine in the middle |
| Complex formula | C14H22CuN6O4 | One copper(II) ion per peptide |
| Molar mass (complex) | approx. 402.9 g/mol | Depends on counterion and hydration state |
| Appearance | Blue to blue-violet solid | Colour arises from copper coordination |
| Common synonyms | Copper tripeptide-1, GHK-Cu | Naming varies between disciplines |
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
== June 1, 1915 (Tuesday) == Gorlice–Tarnów Offensive — German infantry occupied three large forts around Przemyśl after a Russian counterattack failed. British light cruiser HMS Arethusa encountered a German airship on the North Sea and quickly launched a Sopwith seaplane to intercept. However, the pilot mistook smoke from British destroyers as a recall signal and abandoned the chase, ending one of the most promising early opportunities for the interception of an airship by a shipborne aircraft. The 107th Infantry Division of the Imperial German Army was established. The United States Department of the Navy awarded its first contract for an airship to the Connecticut Aircraft Company. Shinano Railway extended the Ōito Line in the Nagano Prefecture, Japan, with station Hakuyachō serving the line. As well, the Geibi Railway extended the Geibi Line in the Okayama Prefecture, Japan, with station Miyoshi serving the line. The second part of the Mandra–Bhaun Railway opened in British India (now Pakistan), connecting Mandra with Bhaun. The Sunset Beach Hotel opened in Glenwood Township, Pope County, Minnesota. It was added to the National Register of Historic Places in 1982.
A saturation spread will include the closed bell and launch and recovery system, saturation habitat, breathing gas supplies and services, all the life support and control equipment, dive equipment stores and workshops, and may also include power supplies and other equipment not directly involved in the diving. It does not include the diving platform as such, for example a DP vessel, or offshore drilling rig, on which the spread is established, or other services such as catering and accommodation for the topside personnel, which would usually be provided to the dive team.
=== Physical properties of NAPLs === The microscopic properties of NAPLs determine their behavior in the field. If they enter the saturated zone, their density relative to that of water will determine how they behave. As a result, NAPLs are categorized based on their relative density into two primary types: light non-aqueous phase liquids (LNAPLs) and dense non-aqueous phase liquids (DNAPLs). LNAPLs tend to float on the water table, while DNAPLs tend to sink downward and, in some conditions, pool at the bottom. Compared to LNAPLs, DNAPLs are more toxic and less biodegradable. There are a variety of parameters specific to the subsurface environment that are important to consider in quantitative models of NAPL behavior. Some of these parameters include soil permeability, moisture, particle size distribution, capillary force, wettability, and ground water flow velocity. The collection of this data is heterogeneous and complex in nature.
While statins are generally well-tolerated, severe adverse effects such as hepatotoxicity and myotoxicity may occur in rarity. Statin-induced hepatotoxicity can cause autoimmune hepatitis and an elevation in serum levels of hepatic enzymes such as alanine aminotransferase, impairing liver function. Myotoxicity is commonly presented with statin-associated muscle symptoms (SAMS), which include myalgia and myositis. In rare cases, they may progress into rhabdomyolysis, a condition manifested by muscle necrosis and myoglobinuria due to heightened creatine kinase levels. Another consequence of taking statins is the risk of developing new-onset diabetes, which is more prominent in individuals with high TG levels and body mass index (BMI). However, the risk is far outweighed by the benefits from statin therapy for the reduction in cardiovascular outcomes. Given the potential of statins to exacerbate liver and muscle abnormalities, contraindications of statins include decompensated liver cirrhosis, acute liver failure, unexplained and persistent elevations of serum transaminases, and myopathy. Moreover, statins are not recommended in pregnancy as they may cause foetal harm because of their mechanism of action. Metabolised by the Cytochrome P450 (CYP450) enzyme, a major metabolic enzyme, simvastatin and lovastatin may accumulate in blood when administered with CYP450 inhibitors. Some of these inhibitors are azole antifungals, macrolides, CCBs, ticagrelor (antiplatelet) and grapefruit juice.
==== Declined ==== Julie Johnson, incumbent U.S. representative from the 24th district (ran in 33rd district) Marc Veasey, incumbent U.S. representative from the 25th district (ran for Tarrant County judge)
Sources: en.wikipedia.org
Based on their interpretation of scriptures such as Acts 15:28, 29 ("Keep abstaining...from blood."), many Jehovah's Witnesses neither consume blood nor accept transfusions of whole blood or its major components: red blood cells, white blood cells, platelets (thrombocytes), and plasma. Members may personally decide whether they will accept medical procedures that involve their own blood or substances that are further fractionated from the four major components.
== Isozymes and allozymes as molecular markers == Population genetics is essentially a study of the causes and effects of genetic variation within and between populations, and in the past, isozymes have been amongst the most widely used molecular markers for this purpose. Although they have now been largely superseded by more informative DNA-based approaches (such as direct DNA sequencing, single nucleotide polymorphisms and microsatellites), they are still among the quickest and cheapest marker systems to develop, and remain (as of 2005) an excellent choice for projects that only need to identify low levels of genetic variation, e.g. quantifying mating systems.
== Honors == Robert M. Scarborough Award for Excellence in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2009) Inducted as an American Chemical Society Fellow (2011) Alfred Burger Award in Medicinal Chemistry, American Chemical Society (2014) Inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame (2014) Edward E. Smissman Award in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2019) IUPAC–Richter Prize in Medicinal Chemistry (2020)
== History == Anti-U1 RNP antibodies were first described in the early 1970s during studies of patients with mixed connective tissue disease. In 1972, rheumatologist Dr, Gordon Sharp and colleagues identified antibodies directed against extractable nuclear antigens (ENAs) in patients who had symptoms of several autoimmune connective tissue diseases. Their work helped establish mixed connective tissue disease (MCTD) as a distinct clinical syndrome and made anti-U1 RNP antibodies an important laboratory discovery in rheumatology. The discovery of anti-U1 RNP antibodies also improved the understanding of autoimmune connective tissue disease. Before these antibodies were identified, many patients with overlapping symptoms were difficult to classify because their conditions shared characteristics of several different autoimmune disorders. Identifying anti-U1 RNP antibodies gave healthcare physicians another way to recognize patterns of disease and support the diagnosis of mixed connective tissue disease. Although the antibodies are not exclusive to MCTD, they remain one of the most characteristic scientific findings associated with the condition. Since their discovery, advances in immunology and laboratory testing have improved the ability to detect anti-U1 RNP antibodies. Early testing methods were time-consuming and performed mainly in research laboratories, but newer techniques such as enzyme-linked immunosorbent assays (ELISA), immunoblotting, and multiplex immunoassays have made testing faster and more widely available.
Sources: en.wikipedia.org
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.
The sequence was identified in human plasma in 1973. Early work examined its presence in blood and its proposed role in tissue repair. The copper-binding property was characterized afterward and became the focus of much later research.
The tripeptide has been measured in human plasma and other biological fluids. Whether it circulates mainly as the copper complex or as the free peptide remains an open question. Natural concentrations are low and difficult to measure reliably.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.